Drugs / M207
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04969497 | Jun → Sep 2021 | migraine disorder | Zosano Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03978403 | May → Jun 2019 | migraine disorder | Zosano Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03708744 | Nov 2018 | migraine disorder | Zosano Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03708744 ↗ |
| Route | Topical | “M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)” NCT03708744 ↗ |